Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Front Immunol. 2021 Mar 26;12:647954. doi: 10.3389/fimmu.2021.647954. eCollection 2021.
Allergy is a disorder owing to hyperimmune responses to a particular kind of substance like food and the disease remains a serious healthcare burden worldwide. This unpleasant and sometimes fatal allergic disease has been tackled vigorously by allergen-specific immunotherapy over a century, but the progress made so far is far from satisfactory for some allergies. Herein, we introduce innovative, allergen powder-based epicutaneous immunotherapies (EPIT), which could potentially serve to generate a new stream of technological possibilities that embrace the features of super safety and efficacious immunotherapy by manipulating the plasticity of the skin immune system sufficient delivery of not only allergens but also tolerogenic adjuvants. We attempt to lay a framework to help understand immune physiology of the skin, epicutaneous delivery of powdered allergy, and potentials for tolerogenic adjuvants. Preclinical and clinical data are reviewed showing that deposition of allergen powder into an array of micropores in the epidermis can confer significant advantages over intradermal or subcutaneous injection of aqueous allergens or other epicutaneous delivery systems to induce immunological responses toward tolerance at little risk of anaphylaxis. Finally, the safety, cost-effectiveness, and acceptability of these novel EPITs are discussed, which offers the perspective of future immunotherapies with all desirable features.
过敏是一种由于对特定物质(如食物)的超免疫反应引起的疾病,它仍然是全球范围内严重的医疗保健负担。一个多世纪以来,针对过敏原的特异性免疫疗法一直在积极应对这种令人不快且有时致命的过敏性疾病,但迄今为止,对于某些过敏症来说,所取得的进展还远远不够。在此,我们介绍了创新的基于过敏原粉末的经皮免疫疗法(EPIT),它有可能通过操纵皮肤免疫系统的可塑性来产生新的技术可能性,为超级安全性和有效的免疫疗法提供支持,从而充分传递过敏原和免疫耐受佐剂。我们试图为理解皮肤的免疫生理学、过敏原粉末的经皮给药以及免疫耐受佐剂的潜力奠定一个框架。回顾了临床前和临床数据,这些数据表明,将过敏原粉末沉积在表皮中的一系列微孔中,可以显著优于皮内或皮下注射水性过敏原或其他经皮给药系统,从而在很少发生过敏反应的风险下诱导对免疫耐受的免疫反应。最后,讨论了这些新型 EPIT 的安全性、成本效益和可接受性,为具有所有理想特征的未来免疫疗法提供了新视角。